---
title: Laboratory Medicine
order: 2
category: Clinical Pathology
status: complete
last_updated: '2025-01-09'
---

# Laboratory Medicine

## Overview

Laboratory medicine is the clinical discipline concerned with the analysis of specimens from patients for diagnostic, prognostic, and therapeutic monitoring purposes. It encompasses the entire testing process from test selection through result interpretation, emphasizing quality assurance, standardization, and evidence-based practice. Laboratory medicine provides objective data that influences approximately 70% of clinical decisions, making it fundamental to modern healthcare delivery.

### Historical Development
- Ancient uroscopy to modern automated analyzers
- Development of reference methods and standardization
- Quality management systems and accreditation
- Integration of molecular and genetic testing
- Point-of-care and personalized medicine

### Scope of Practice
- Test menu development and validation
- Quality control and quality assurance
- Result interpretation and clinical consultation
- Laboratory management and operations
- Research and development of new methods
- Education and training of laboratory personnel

## Laboratory Organization and Management

### Laboratory Structure

#### Core Laboratory
- **Chemistry**: Routine and specialized biochemical tests
- **Hematology**: Blood cell counts and coagulation
- **Microbiology**: Culture and identification of pathogens
- **Immunology**: Antibody and antigen testing
- **Blood bank**: Transfusion services and compatibility testing

#### Specialized Sections
- **Molecular diagnostics**: Nucleic acid-based testing
- **Cytogenetics**: Chromosome analysis
- **Flow cytometry**: Cell sorting and phenotyping
- **Toxicology**: Drug screening and poisoning
- **Endocrinology**: Hormone assays

#### Point-of-Care Testing (POCT)
- Bedside glucose monitoring
- Arterial blood gas analysis
- Cardiac troponin testing
- Pregnancy tests
- Coagulation monitoring (INR)

### Laboratory Accreditation

#### CLIA Regulations
- **Waived tests**: Simple tests with low error risk
- **Moderate complexity**: Most automated tests
- **High complexity**: Specialized testing requiring expertise
- **Personnel requirements**: Director, supervisor, technologist qualifications
- **Quality control**: Daily controls, proficiency testing
- **Inspection**: Biennial surveys

#### CAP Accreditation
- Comprehensive checklist requirements
- Peer-reviewed inspection process
- Proficiency testing programs
- Quality improvement initiatives
- More stringent than CLIA minimum standards

#### ISO 15189
- International standard for medical laboratories
- Quality management system requirements
- Technical competence requirements
- Continual improvement focus
- Risk management approach

## Pre-Analytical Phase

### Test Selection

#### Clinical Indication
- Screening vs. diagnostic testing
- Monitoring disease progression
- Therapeutic drug monitoring
- Prognosis and risk stratification
- Cost-effectiveness considerations

#### Test Characteristics
- **Sensitivity**: Ability to detect disease when present
- **Specificity**: Ability to exclude disease when absent
- **Positive predictive value (PPV)**: Probability of disease given positive test
- **Negative predictive value (NPV)**: Probability of no disease given negative test
- **Likelihood ratios**: Odds of disease given test result

#### Evidence-Based Test Selection
- Clinical practice guidelines
- Systematic reviews and meta-analyses
- Local protocols and pathways
- Laboratory stewardship programs
- Avoiding unnecessary testing

### Patient Preparation

#### Fasting Requirements
- **8-12 hour fast**: Lipid panels, glucose tolerance tests
- **Overnight fast**: Most chemistry panels
- **No fasting required**: Complete blood count, most tests
- **Water allowed**: Unless specific restriction

#### Timing Considerations
- **Diurnal variation**: Cortisol, testosterone, iron
- **Peak and trough levels**: Therapeutic drug monitoring
- **Post-dose timing**: Antibiotic levels
- **Exercise effects**: Creatine kinase, lactate

#### Medication Effects
- Drug interference with assays
- Therapeutic vs. toxic levels
- Timing of specimen collection
- Documentation of medications

### Specimen Collection

#### Venipuncture Technique
- Patient identification verification
- Proper site selection and preparation
- Tourniquet application (<1 minute)
- Needle insertion and tube filling
- Order of draw to prevent contamination
- Post-collection care and labeling

#### Order of Draw
1. Blood culture bottles
2. Coagulation tubes (light blue)
3. Serum tubes (red or gold)
4. Heparin tubes (green)
5. EDTA tubes (purple)
6. Glycolysis inhibitor tubes (gray)

#### Special Collection Procedures
- **Arterial blood gas**: Radial artery puncture, anaerobic collection
- **Capillary collection**: Heel stick for neonates, finger stick
- **24-hour urine**: Complete collection with preservatives
- **Timed specimens**: Specific collection intervals
- **Cerebrospinal fluid**: Sterile technique, sequential tubes

### Specimen Processing and Handling

#### Centrifugation
- Speed and time standardization
- Temperature control
- Complete clot formation before centrifugation
- Gel separator tubes

#### Storage Conditions
- **Room temperature**: Short-term, some tests
- **Refrigerated (2-8°C)**: Most routine chemistry
- **Frozen (-20°C or -80°C)**: Long-term storage, specialized tests
- **Light protection**: Bilirubin, vitamin B12, porphyrins

#### Specimen Stability
- Time limits for analysis
- Temperature effects on analytes
- Anticoagulant selection
- Preservatives and additives

#### Common Pre-Analytical Errors
- **Hemolysis**: Rough handling, small needle gauge
- **Lipemia**: Non-fasting specimen
- **Icterus**: Severe hyperbilirubinemia
- **Contamination**: IV fluid dilution
- **Clotting**: Insufficient anticoagulant

## Analytical Phase

### Analytical Methods

#### Spectrophotometry
- **Principle**: Light absorption at specific wavelengths
- **Applications**: Most chemistry analytes
- **Types**: UV-visible, atomic absorption
- **Advantages**: Simple, cost-effective
- **Limitations**: Interference from hemolysis, lipemia

#### Immunoassays
- **Competitive**: Labeled antigen competition
- **Sandwich**: Antibody capture and detection
- **Types**: ELISA, CLIA, ECLIA
- **Applications**: Hormones, tumor markers, drugs
- **High sensitivity and specificity**

#### Chromatography
- **Gas chromatography (GC)**: Volatile compounds
- **High-performance liquid chromatography (HPLC)**: Non-volatile compounds
- **Mass spectrometry coupling (GC-MS, LC-MS)**: Gold standard for many tests
- **Applications**: Drugs, hormones, metabolites

#### Electrophoresis
- **Protein electrophoresis**: Serum protein patterns
- **Hemoglobin electrophoresis**: Hemoglobinopathies
- **Isoenzyme separation**: CK-MB, LD isoforms
- **Capillary electrophoresis**: High resolution

#### Molecular Methods
- **PCR**: Gene amplification and detection
- **Real-time PCR**: Quantitative analysis
- **DNA sequencing**: Mutation detection
- **Microarray**: Gene expression profiling
- **Next-generation sequencing**: Comprehensive genomic analysis

### Automation

#### Advantages of Automation
- Increased throughput and efficiency
- Reduced turnaround time
- Improved precision and accuracy
- Decreased manual errors
- Better tracking and documentation
- Cost savings through economies of scale

#### Automated Analyzers
- **Random access**: Any test, any sequence
- **Batch processing**: Same test, multiple samples
- **Discrete analysis**: Individual reaction vessels
- **Continuous flow**: Segmented stream analysis
- **Integration**: Track-based specimen routing

#### Middleware
- Auto-validation of results
- Delta check verification
- Reflex testing protocols
- Quality control monitoring
- Instrument connectivity

### Quality Control

#### Internal Quality Control

##### Daily QC
- **Control materials**: Known concentration samples
- **Multiple levels**: Normal, abnormal ranges
- **Acceptance criteria**: Mean ± 2 SD or 3 SD
- **Westgard rules**: Multi-rule quality control
- **Documentation**: QC logs and charts

##### Westgard Multi-Rules
- **1-2s**: Warning rule (investigate)
- **1-3s**: Reject run, random error
- **2-2s**: Reject run, systematic error
- **R-4s**: Reject run, random error
- **4-1s**: Reject run, systematic error
- **10x**: Reject run, systematic error

#### Levey-Jennings Charts
- Graphical display of QC results
- Mean and SD lines
- Trend detection
- Shift identification
- Visual quality monitoring

#### Calibration
- **Frequency**: Daily, with reagent change, or as needed
- **Calibrators**: Traceable to reference materials
- **Verification**: Post-calibration QC
- **Documentation**: Calibration records

### External Quality Assessment

#### Proficiency Testing
- **Requirement**: CLIA mandates for most tests
- **Frequency**: Usually 3 times per year
- **Evaluation**: Comparison to peer laboratories
- **Grading**: Acceptable vs. unacceptable performance
- **Follow-up**: Investigation of failures

#### Reference Laboratory Comparison
- Split sample analysis
- Correlation studies
- Method comparison
- Bias determination

### Method Validation and Verification

#### Analytical Performance Characteristics

##### Accuracy
- **Definition**: Closeness to true value
- **Assessment**: Reference method comparison
- **Expression**: Bias or % recovery
- **Goal**: Minimize systematic error

##### Precision
- **Definition**: Reproducibility of results
- **Types**: Within-run, between-run, between-day
- **Assessment**: Replicate analysis, coefficient of variation
- **Expression**: Standard deviation, CV%
- **Goal**: Minimize random error

##### Analytical Sensitivity
- **Limit of detection (LOD)**: Lowest detectable concentration
- **Limit of quantification (LOQ)**: Lowest reliably quantifiable concentration
- **Clinical sensitivity**: Detect clinically significant levels

##### Analytical Specificity
- **Interference testing**: Hemolysis, lipemia, icterus
- **Cross-reactivity**: Related compounds
- **Matrix effects**: Specimen type differences

##### Linearity
- **Definition**: Range of proportional response
- **Assessment**: Dilution or spiking studies
- **Reportable range**: Validated measurement interval
- **Dilution protocols**: For values exceeding linearity

##### Reference Interval Verification
- **Transference**: Verify manufacturer's ranges
- **Sample size**: Minimum 20 healthy individuals
- **Population-specific**: Age, sex, ethnicity considerations
- **Statistical methods**: 95% confidence intervals

## Post-Analytical Phase

### Result Reporting

#### Turnaround Time (TAT)
- **Definition**: Time from order to result availability
- **Monitoring**: TAT metrics by test and priority
- **Goals**: STAT <60 minutes, routine <24 hours
- **Improvement**: Process optimization

#### Critical Values (Panic Values)
- **Definition**: Life-threatening results requiring immediate notification
- **Examples**: Glucose <40 or >500 mg/dL, K+ <2.5 or >6.5 mEq/L
- **Protocol**: Direct communication with healthcare provider
- **Documentation**: Read-back verification, time, recipient
- **Follow-up**: Ensure clinical action taken

#### Result Format
- Numerical values with units
- Reference ranges (age/sex-specific)
- Flags (high, low, critical)
- Interpretive comments when appropriate
- Delta checks for significant changes
- Previous results for comparison

### Result Interpretation

#### Reference Intervals
- **Definition**: Range expected in healthy population
- **Central 95%**: Excludes extreme 2.5% on each end
- **Population-specific**: Age, sex, race, pregnancy
- **Individual variation**: Within-person vs. between-person
- **Biological variation**: Consider when interpreting changes

#### Clinical Decision Limits
- **Therapeutic ranges**: Drug monitoring
- **Diagnostic cutoffs**: Disease vs. health
- **Risk stratification**: Cardiovascular risk scores
- **Treatment thresholds**: Initiate or modify therapy

#### Delta Checks
- **Definition**: Comparison with previous results
- **Absolute change**: Difference in values
- **Relative change**: Percentage change
- **Time interval**: Hours to days
- **Investigation**: Large changes may indicate error

#### Interfering Substances
- **Hemolysis**: Falsely ↑ K+, LD, AST, ↓ LD
- **Lipemia**: Turbidity affects spectrophotometry
- **Icterus**: Spectral interference at certain wavelengths
- **Paraproteins**: Interference in immunoassays
- **Heterophile antibodies**: False positive immunoassays
- **Biotin**: Interference in streptavidin-biotin assays

### Laboratory Information Systems (LIS)

#### Core Functions
- Order entry and management
- Specimen tracking and labeling
- Result entry and validation
- Quality control management
- Report generation and delivery
- Data storage and retrieval
- Billing and compliance

#### Integration
- **EHR connectivity**: Bidirectional communication
- **Instrument interfaces**: Automated result transmission
- **Middleware**: Auto-validation and reflex testing
- **Decision support**: Reference ranges, interpretive comments
- **Patient portal**: Online result access

#### Data Management
- **Security**: HIPAA compliance, access controls
- **Backup**: Redundancy and disaster recovery
- **Archiving**: Long-term storage requirements
- **Analytics**: Quality metrics, utilization review
- **Audit trails**: Complete transaction logging

## Laboratory Stewardship

### Appropriate Test Utilization

#### Overutilization
- **Consequences**: Unnecessary costs, incidental findings
- **Causes**: Defensive medicine, lack of guidelines
- **Solutions**: Education, decision support, feedback

#### Underutilization
- **Consequences**: Missed diagnoses, delayed treatment
- **Causes**: Cost concerns, lack of awareness
- **Solutions**: Guideline implementation, access improvement

#### Choosing Wisely
- Evidence-based recommendations
- Avoiding low-value tests
- Alternative testing strategies
- Cost-conscious ordering

### Clinical Consultation

#### Pathologist as Consultant
- Test selection guidance
- Result interpretation
- Unusual findings explanation
- Quality issues resolution
- New test evaluation

#### Communication
- Direct phone consultation
- Email and messaging
- Laboratory bulletins
- Education sessions
- Multidisciplinary conferences

## Point-of-Care Testing (POCT)

### Advantages
- Rapid results at patient location
- Immediate clinical decision-making
- Reduced specimen volume
- Patient convenience
- Decreased turnaround time

### Challenges
- Quality control oversight
- Operator training and competency
- Documentation and connectivity
- Cost per test
- Regulatory compliance

### Common POCT Applications
- **Glucose monitoring**: Diabetes management
- **Blood gas analysis**: Critical care
- **Cardiac markers**: Chest pain evaluation
- **Coagulation**: INR monitoring
- **Pregnancy tests**: Qualitative hCG
- **Urinalysis**: Dipstick testing
- **Infectious disease**: Rapid strep, influenza

### Quality Management
- Training and competency assessment
- Daily quality control
- Proficiency testing participation
- Correlation with central lab
- Preventive maintenance
- Documentation and record keeping

## Specialized Testing

### Therapeutic Drug Monitoring (TDM)

#### Indications
- Narrow therapeutic index
- Variable pharmacokinetics
- Dose-response relationship
- Toxicity monitoring
- Compliance assessment

#### Common Monitored Drugs
- **Antibiotics**: Vancomycin, gentamicin, amikacin
- **Anticonvulsants**: Phenytoin, valproic acid, carbamazepine
- **Immunosuppressants**: Tacrolimus, cyclosporine, sirolimus
- **Cardiac drugs**: Digoxin, amiodarone
- **Psychiatric**: Lithium

#### Interpretation
- Peak and trough levels
- Time since last dose
- Renal and hepatic function
- Drug interactions
- Clinical response

### Toxicology Testing

#### Drug Screening
- **Immunoassay**: Initial screening
- **Confirmation**: GC-MS or LC-MS
- **Common drugs**: Amphetamines, cannabinoids, cocaine, opiates
- **Limitations**: Cross-reactivity, cutoff concentrations

#### Heavy Metals
- Lead, mercury, arsenic
- Occupational exposure
- Environmental contamination
- Chelation therapy monitoring

### Tumor Markers

#### Clinical Applications
- **Limited screening utility**: Low specificity
- **Diagnostic aid**: With imaging and clinical findings
- **Monitoring**: Treatment response, recurrence
- **Prognosis**: Risk stratification

#### Common Markers
- **PSA**: Prostate cancer
- **CEA**: Colorectal, other GI cancers
- **CA 125**: Ovarian cancer
- **CA 19-9**: Pancreatic cancer
- **AFP**: Hepatocellular carcinoma, germ cell tumors
- **hCG**: Germ cell tumors, gestational trophoblastic disease

## Error Management

### Types of Errors

#### Pre-Analytical (60-70%)
- Wrong patient/specimen
- Incorrect collection
- Hemolysis
- Insufficient volume
- Lost specimen
- Delayed transport

#### Analytical (15-20%)
- Calibration failure
- Reagent problems
- Instrument malfunction
- Pipetting errors
- Contamination

#### Post-Analytical (15-20%)
- Transcription errors
- Delayed reporting
- Critical value not called
- Wrong result to wrong patient
- Misinterpretation

### Error Detection and Prevention

#### Six Sigma Methodology
- Define, Measure, Analyze, Improve, Control (DMAIC)
- Process capability assessment
- Defect rate reduction
- Continuous improvement

#### Root Cause Analysis
- Systematic investigation
- Contributing factors identification
- Corrective actions
- Prevention strategies
- Follow-up verification

#### Lean Principles
- Waste elimination
- Process streamlining
- Value-added steps focus
- Continuous flow
- Pull systems

## Emerging Technologies

### Automation and Robotics
- Total laboratory automation (TLA)
- Specimen processing automation
- Reduced manual handling
- Improved tracking
- Decreased errors

### Artificial Intelligence and Machine Learning
- Auto-validation algorithms
- Pattern recognition
- Predictive analytics
- Personalized reference intervals
- Quality control optimization

### Mass Spectrometry
- Clinical chemistry applications
- Steroid hormone analysis
- Vitamin D testing
- Therapeutic drug monitoring
- Microbial identification (MALDI-TOF)

### Digital Health
- Wearable biosensors
- Continuous glucose monitoring
- Remote patient monitoring
- Telemedicine integration
- Mobile health applications

## Key Points

- Laboratory medicine provides objective data for 70% of clinical decisions
- Quality control ensures accurate and reliable results through systematic monitoring
- Pre-analytical errors account for 60-70% of laboratory errors
- Reference intervals must be interpreted in clinical context with patient-specific factors
- Critical values require immediate communication to prevent patient harm
- Laboratory stewardship promotes appropriate test utilization and cost-effectiveness
- Point-of-care testing provides rapid results but requires robust quality management
- Automation improves efficiency, reduces errors, and enhances laboratory workflow
- Method validation ensures analytical performance meets clinical requirements
- Continuous quality improvement is essential for laboratory excellence

## References

1. McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2021.
2. Clinical and Laboratory Standards Institute (CLSI). Quality Management System: Development and Management of Laboratory Documents. CLSI guideline QMS02. 7th ed. 2019.
3. Westgard JO. Basic Quality Management System for the Clinical Laboratory. 2nd ed. Madison, WI: Westgard QC; 2012.
4. Food and Drug Administration. Clinical Laboratory Improvement Amendments (CLIA). 42 CFR Part 493. 2003.
5. College of American Pathologists. Laboratory Accreditation Program Checklists. 2024.
6. ISO 15189:2022. Medical laboratories - Requirements for quality and competence. International Organization for Standardization; 2022.
7. Lundberg GD. Acting on significant laboratory results. JAMA. 1981;245(17):1762-1763.
8. Plebani M. Quality indicators to detect pre-analytical errors in laboratory testing. Clin Biochem Rev. 2012;33(3):85-88.
9. Choosing Wisely. American Society for Clinical Pathology: Five Things Physicians and Patients Should Question. 2013.
10. Lewandrowski K, Gregory K, Macmillan D. Assuring quality in point-of-care testing: evolution of technologies, informatics, and program management. Arch Pathol Lab Med. 2011;135(11):1405-1414.
